Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved cabozantinib for patients 12 years of age and older ...

Exelixis has won U.S. Food and Drug Administration expanded approval of its Cabometyx cancer drug for certain patients with advanced neuroendocrine tumors.

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 ...

Because pituitary corticotroph adenomas express somatostatin receptors, somatostatin analogues have been investigated as a potential targeted therapy for the treatment of Cushing's disease.

However, the researchers hypothesized that the cone snail’s version of somatostatin, Consomatin G1, might also selectively target the hormone-regulating receptor SSTR 2 due to its structural ...

Molecular imaging, including somatostatin receptor scintigraphy but more so PET with specific tracers, such as C 11-5HTP or Ga 68-DOTA octreotate, will improve staging and follow-up of therapy in ...

and constitutional symptoms (for example, fatigue) were moderately improved, as was the patients' quality of life. ...somatostatin receptor-targeting radiopharmaceuticals should be a last resort ...